A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and hypertriglycedemia.
| Segment | 2023 | % of Total |
|---|---|---|
Operating Segment | $1M | 100% |
| Metric | TTM | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 0 | 0 | 0 |
| Net Income | -12M | -8.6M | -10M | -14M | -13M | -15M |
| EPS | $-0.25 | $-0.17 | $-0.21 | $-0.31 | $-0.30 | $-0.36 |
| Free Cash Flow | 0 | -7.5M | -9.4M | -11M | -9.1M | -9.1M |
| ROIC | -22.2% | -13.7% | -11.7% | -19.4% | -17.3% | -20.1% |
| Gross Margin | - | - | - | 0.0% | 0.0% | 0.0% |
| Debt/Equity | 0.00 | 0.06 | - | 0.06 | 0.06 | 0.06 |
| Dividends/Share | $0.00 | - | - | $0.00 | $0.00 | $0.00 |
| Operating Income | -13M | -9.9M | -10M | -14M | -14M | -16M |
| Operating Margin | 0.0% | - | - | 0.0% | 0.0% | 0.0% |
| ROE | -27.3% | -13.7% | - | -18.9% | -17.5% | -26.3% |
| Shares Outstanding | 49M | 50M | 48M | 45M | 43M | 41M |
MEDICINOVA INC passes 0 of 9 quality checks, indicating weak fundamentals.
MEDICINOVA INC (MNOV) has a 5-year average return on invested capital (ROIC) of -16.4%. This is below average and may indicate limited pricing power.
MEDICINOVA INC (MNOV) has a market capitalization of $71M. It is classified as a small-cap stock.
MEDICINOVA INC (MNOV) does not currently pay a regular dividend.
MEDICINOVA INC (MNOV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
MEDICINOVA INC (MNOV) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MEDICINOVA INC (MNOV) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
MEDICINOVA INC (MNOV) reported earnings per share (EPS) of $-0.17 in its most recent fiscal year.
MEDICINOVA INC (MNOV) has a return on equity (ROE) of -13.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for MEDICINOVA INC (MNOV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MEDICINOVA INC (MNOV) has a book value per share of $1.24, based on its most recent annual SEC filing.